(S)-3-methyl-2-(4''-(3-methyl-4-phenoxybenzofuran-2-carboxamido)biphenyl-4-ylsulfonamido)butanoic acid | 857076-83-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-3-methyl-2-(4''-(3-methyl-4-phenoxybenzofuran-2-carboxamido)biphenyl-4-ylsulfonamido)butanoic acid
• 英文别名: (2S)-3-methyl-2-[[4-[4-[(3-methyl-4-phenoxy-1-benzofuran-2-carbonyl)amino]phenyl]phenyl]sulfonylamino]butanoic acid
• CAS: 857076-83-6
• 化学式: C₃₃H₃₀N₂O₇S
• 分子量: 598.676
• InChiKey: YWWJREBSMRNZGO-PMERELPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  43
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  143
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  methyl (2S)-3-methyl-2-[[4-[4-[(3-methyl-4-phenoxy-1-benzofuran-2-carbonyl)amino]phenyl]phenyl]sulfonylamino]butanoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 18.0h， 生成 (S)-3-methyl-2-(4''-(3-methyl-4-phenoxybenzofuran-2-carboxamido)biphenyl-4-ylsulfonamido)butanoic acid
  参考文献：
  名称：

  3,4-Disubstituted benzofuran P1′ MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding

  摘要：

  Potent 3,4-disubstituted benzofuran P1' MMP-13 inhibitors have been prepared. Selectivity over MMP-2 was achieved through a substituent at the C4 position of the benzofuran P1' moiety of the molecule. By replacing a backbone benzene with a pyridine and valine with threonine, compounds (e. g., 44) with greatly reduced plasma protein binding were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.008

文献信息

• [EN] BIARYL SULFONAMIDES AS MMP INHIBITORS<br/>[FR] SULFONAMIDES BIARYLIQUES INHIBITEURS DE MMP
  申请人：WYETH CORP

  公开号：WO2005061477A1

  公开（公告）日：2005-07-07

  The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors: Formule (I).

  本发明涉及联苯磺酰胺及其用途，例如，作为金属蛋白酶抑制剂：式（I）。
• Biaryl Sulfonamides and Methods for Using Same
  申请人：Levin Jeremy Ian

  公开号：US20100137298A1

  公开（公告）日：2010-06-03

  The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.

  本发明涉及双芳基磺酰胺及其用途，例如作为金属蛋白酶抑制剂。
• US7420001B2
  申请人：——

  公开号：US7420001B2

  公开（公告）日：2008-09-02
• 3,4-Disubstituted benzofuran P1′ MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding
  作者：Wei Li、Yonghan Hu、Jianchang Li、Jennifer R. Thomason、Dianne DeVincentis、Xuemei Du、Junjun Wu、Rajeev Hotchandani、Thomas S. Rush、Jerauld S. Skotnicki、Steve Tam、Priya S. Chockalingam、Elisabeth A. Morris、Jeremy I. Levin

  DOI：10.1016/j.bmcl.2009.07.008

  日期：2009.8

  Potent 3,4-disubstituted benzofuran P1' MMP-13 inhibitors have been prepared. Selectivity over MMP-2 was achieved through a substituent at the C4 position of the benzofuran P1' moiety of the molecule. By replacing a backbone benzene with a pyridine and valine with threonine, compounds (e. g., 44) with greatly reduced plasma protein binding were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.